Overview

Comprehensive Analysis of Relapse in Multiple Sclerosis

Status:
Unknown status
Trial end date:
2015-01-01
Target enrollment:
0
Participant gender:
All
Summary
This study will determine changes in: 1) the immune activity, characterized as the "immunorepertoire;" 2) 7 Tesla MRI brain images; 3) clinical outcomes; and 4) patient reported quality of life outcomes in subjects with relapsing-remitting multiple sclerosis who are treated with Acthar Gel.
Phase:
N/A
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Tanner Foundation for Multiple Sclerosis
Collaborators:
Auburn University MRI Research Center
iReportoire Inc
Mallinckrodt
Treatments:
Adrenocorticotropic Hormone
Criteria
Inclusion Criteria:

- Patients will be eligible to participate in the study if:

They were diagnosed with Relapsing-Remitting Multiple Sclerosis within 1 year of their
participation in the study Are established patients of the Tanner Center for MS Seek care
for relapse within 72 hours of onset Are between the ages of 19 and 65 inclusively.

Relapse will be confirmed and defined as the acute worsening of function that lasts for at
least 24 hours with any of the manifestations of Central Nervous System relapses (excluding
spinal cord) including:

Brain stem syndrome Optic neuritis Cerebellar syndromes Hemi-motor/sensory events Males and
Females are both eligible Patients of any race or ethnicity are eligible Are not pregnant
(as confirmed by pregnancy test at the time of enrollment) or nursing Have no known
contraindicating conditions (see exclusions)

Exclusion Criteria:

- Potential participants will be excluded if they do not meet the above criteria, and
also if:

They are currently being treated for MS with the any of the following disease-modifying
drugs: Tysabri, Gilenya, Aubagio, Tecfidera They have a history of experiencing significant
adverse reactions to corticosteroids They are deemed by Dr Riser to be better served with
an intervention other than Acthar Gel to treat their current MS relapse Are pregnant or
nursing

Are known to have any of the contraindicating conditions:

Scleroderm Osteoporosis Systemic fungal infections Ocular herpes simplex Recent surgery
History of or presence of peptic ulcer Congestive heart failure Uncontrolled hypertension
Adreno-cortical insufficiency, hyper-function or sensitivity Sensitivity to proteins of
porcine origin